Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases
- 31 August 2010
- journal article
- review article
- Published by Elsevier BV in Drug Discovery Today
- Vol. 15 (15-16), 622-629
- https://doi.org/10.1016/j.drudis.2010.06.011
Abstract
No abstract availableKeywords
This publication has 114 references indexed in Scilit:
- PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinomaHuman Pathology, 2009
- Evidence for Statin Pleiotropy in HumansCirculation, 2009
- Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatinBlood Coagulation & Fibrinolysis, 2008
- The inhaled Rho kinase inhibitor Y-27632 protects against allergen-induced acute bronchoconstriction, airway hyperresponsiveness, and inflammationAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2008
- Deficiency of ROCK1 in bone marrow‐derived cells protects against atherosclerosis in LDLR −/− miceThe FASEB Journal, 2008
- Rho‐associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferationDevelopmental Dynamics, 2002
- Inflammation in atherosclerosisNature, 2002
- Rho-kinase Inhibitors: Pharmacomodulations on the Lead Compound Y-32885Journal of Enzyme Inhibition and Medicinal Chemistry, 2002
- Antianginal effects of hydroxyfasudil, a Rho‐kinase inhibitor, in a canine model of effort anginaBritish Journal of Pharmacology, 2001
- Specificity and mechanism of action of some commonly used protein kinase inhibitorsBiochemical Journal, 2000